Status:
COMPLETED
A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to find out the frequency of the I50L substitution among patients experiencing treatment failure on an atazanavir-containing regimen.
Eligibility Criteria
Inclusion
- Atazanavir - containing antiretroviral regimen
- Confirmed virologic failure defined as either:
- HIV RNA by PCR greater than or equal to 1000 copies/mL after achieving a value of \<400 copies/mL on at least 2 consecutive measurements or
- HIV RNA greater than or equal to 1000 copies/mL after 24 weeks of continuous therapy
- At least 18 years old
Exclusion
- Unable to give informed consent
- Prisoners or subjects involuntarily incarcerated for treatment of psychiatric or physical illness
Key Trial Info
Start Date :
September 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT00135447
Start Date
September 1 2004
End Date
September 1 2009
Last Update
April 14 2011
Active Locations (84)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Phoenix, Arizona, United States, 85006
2
Vista Medical Partners
Beverly Hills, California, United States, 90210
3
AIDS Healthcare Foundation
Beverly Hills, California, United States, 90211
4
AltaMed Health Services Corporation
Los Angeles, California, United States, 90022